AUS
NZ
UK
CA
USA
IND
Uscom Limited (ASX:UCM), an Australian medical device firm formerly producing non-invasive haemodynamic monitoring systems, has completed the sale of all its subsidiaries for $2.591 million. Shareholders approved the transaction on 7 November 2025, with the deal finalized between 1 and 31 December 2025. Post-sale, Uscom remains listed on the ASX but is currently suspended from trading as management pursues a strategic acquisition aligned with shareholder expectations.
Key Points
- Uscom Limited (UCM) specialized in non-invasive haemodynamic monitoring devices for clinical use.
- The company completed the disposal of all subsidiaries for $2.591 million during December 2025.
- Q2 FY2026 customer receipts declined to $0.211 million from $0.505 million in the previous quarter amid business transition.
- As of 31 December 2025, Uscom held $0.002 million in cash and remains suspended from ASX trading pending acquisition activity.
Subsidiary Disposal Completed, Business Transition Underway
Uscom Limited confirmed the completion of its asset sale in the quarter ending 31 December 2025. The company operated its core business from 1 July to 30 November 2025 before shifting focus to finalizing the asset sale approved at the 7 November 2025 AGM. The transaction involved selling all subsidiaries for $2.591 million, marking a major structural shift.
The quarter was split between ongoing operations through November and transaction finalization in December, explaining the mixed financial results. Following the sale, Uscom remains ASX-listed but suspended from trading as management actively seeks an acquisition opportunity that meets commercial and shareholder goals.
Revenue Drop and Cash Flow Improvements During Transition
Customer receipts fell to $0.211 million in Q2 FY2026 from $0.505 million in the prior quarter, reflecting the wind-down phase ahead of the subsidiary sale. Operating cash outflow improved to $0.397 million from $0.894 million previously.
Manufacturing and operating expenses decreased to $0.105 million from $0.252 million, while administration and corporate costs rose to $0.713 million due to asset sale management and compliance expenses, including $0.013 million in director fees. Government grants and tax incentives totaling $0.464 million year-to-date partially offset costs.
Cash Position and Financing Activities Post-Transaction
As of 31 December 2025, cash on hand was $0.002 million, reflecting significant cash use earlier in the year. Net operating cash outflow for the six months to 31 December was $1.291 million. The company maintained bank balances without overdraft usage, indicating cash conservation efforts.
Year-to-date net financing activities added $0.329 million, including $0.700 million in borrowings, $0.169 million in lease repayments, and a $0.200 million short-term loan to Uscom Australia Pty Ltd. No new equity or convertible debt was issued. Investing cash outflows were minimal at $0.003 million related to intellectual property.
Background on Medical Device Operations and Market Focus
Uscom previously focused on manufacturing and selling non-invasive haemodynamic monitoring systems for clinical cardiovascular assessment. These devices served hospitals and clinics requiring diagnostic evaluation of cardiac and circulatory function.
The sale of all subsidiaries signals a strategic pivot from medical device manufacturing to an acquisition-driven business model. This approach is common for listed companies aiming to redeploy capital or enter new markets more efficiently than organic growth.
Shareholder Approval and Transaction Governance
The asset sale was approved by shareholders at the 7 November 2025 AGM, complying with ASX Listing Rules for major transactions. This endorsement authorized management to execute the disposal, which was completed within four to five weeks, indicating pre-advanced negotiations or deal structures. The transaction closure within the calendar year ensured clear financial separation.
Trading Suspension and Acquisition Strategy
Following the asset sale, Uscom remains listed but suspended from ASX trading. Suspension protects investors during significant corporate changes and while material undisclosed acquisition information may exist. Management is actively evaluating acquisition targets to fulfill commercial objectives and shareholder expectations.
During suspension, Uscom functions as an acquisition vehicle, leveraging its remaining capital and listed status to create value through M&A. Specific acquisition criteria have not been disclosed, with further announcements anticipated.
Reduction in Advertising and Marketing Expenses Amid Wind-Down
Advertising and marketing expenses declined to $0.308 million in the quarter from $0.358 million previously, totaling $0.358 million year-to-date. This decrease aligns with the business wind-down and transition to an acquisition-focused structure. Staff costs also dropped to $0.086 million for the quarter, totaling $0.962 million year-to-date, reflecting a leaner operational footprint.
Government Grants and Tax Incentives Support
Uscom received $0.464 million in government grants and tax incentives during the six months ended 31 December 2025. These funds helped offset operating cash outflows amid declining revenues and business transition. Such support likely included R&D tax credits and export incentives, providing vital liquidity distinct from revenues or financing.
Six-Month Financial Overview and Cash Flow Trends
Over the six months to 31 December 2025, customer receipts totaled $0.715 million, primarily generated in the first quarter. Net operating cash outflow was $1.291 million, with minimal R&D expenditure of $0.004 million. The results reflect an accelerating wind-down and shift to acquisition mode, with limited financial runway absent a timely acquisition or additional funding.
